LABT Financials

Income Statement
MetricQ2 2026
Revenue
0
Cost of Revenue
0
Gross Profit
0
Operating Expenses
3.8M
R&D
503.0K
SG&A
3.3M
Operating Income
-3789660
EBITDA
-3788502
Net Income
-3772008
EPS (Basic)
$-2.75
EPS (Diluted)
$-2.75
Shares (Diluted)
1.4M
MarketsMoversWatchlist
Lakewood-Amedex Biotherapeutics (LABT) — Financials